Hospital
Southern Hills Medical Center, LLC
Southern Hills Medical Center, LLC was paid $19.79M by Medicaid between Jan 2018 and Dec 2024, across 215 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoSOUTHERN HILLS MEDICAL CENTER, LLC
LAS VEGAS, NV 89148
LAS VEGAS, NV 89148
33aNPI1457306359assigned 05/23/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.79M
24GClaims824,274
24DCodes billed215
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#12 of 36
Median peer was paid$7.64M
This provider vs. median2.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,436 | $573K | |
| 2019 | 109,919 | $2.63M | |
| 2020 | 119,811 | $2.82M | |
| 2021 | 150,663 | $3.68M | |
| 2022 | 154,729 | $4.22M | |
| 2023 | 151,336 | $3.40M | |
| 2024incomplete | 117,380 | $2.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 53,173 | 46,615 | $4.00M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 39,911 | 35,018 | $3.46M |
| G0378 | Hospital observation service, per hour | 11% | 13,381 | 7,550 | $2.16M |
| 41899 | Unlisted procedure, dentoalveolar structures | 5.6% | 1,471 | 1,324 | $1.10M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.3% | 6,938 | 6,470 | $842K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.2% | 9,818 | 8,538 | $831K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.3% | 24,341 | 21,188 | $656K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 9,151 | 8,684 | $631K |
| 93975 | 2.5% | 3,415 | 3,004 | $503K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.3% | 14,548 | 11,515 | $461K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.1% | 5,099 | 4,898 | $414K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 12,228 | 10,083 | $341K |
203 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.4% | 2,160 | $286K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 5,275 | $198K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 519 | $196K |
| 80053 | Comprehensive metabolic panel | <1% | 31,251 | $159K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,111 | $154K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,093 | $146K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,260 | $136K |
| 71045 | Radiologic examination, chest; single view | <1% | 19,139 | $116K |
| 85027 | <1% | 56,097 | $115K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 4,248 | $103K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,739 | $100K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,682 | $98K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,815 | $98K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,148 | $97K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,056 | $95K |
| 76830 | Ultrasound, transvaginal | <1% | 1,776 | $92K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,371 | $89K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,157 | $73K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,336 | $72K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 87 | $72K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 18,395 | $71K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,935 | $70K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,498 | $60K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 26,910 | $59K |
| 93971 | <1% | 1,464 | $55K | |
| 83880 | <1% | 4,349 | $51K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,371 | $49K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,895 | $44K |
| 80076 | <1% | 12,108 | $42K | |
| 84484 | <1% | 10,115 | $42K | |
| 84703 | <1% | 15,718 | $42K | |
| 83690 | <1% | 17,243 | $41K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,900 | $41K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,367 | $40K |
| 73564 | <1% | 1,810 | $37K | |
| 81001 | <1% | 20,752 | $37K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 575 | $36K |
| 87070 | <1% | 3,328 | $35K | |
| 96376 | <1% | 5,367 | $31K | |
| 87430 | <1% | 4,975 | $31K | |
| 84702 | <1% | 4,382 | $30K | |
| 73130 | <1% | 1,542 | $28K | |
| 73610 | <1% | 1,490 | $28K | |
| 73630 | <1% | 1,710 | $28K | |
| 90715 | <1% | 1,252 | $26K | |
| 87040 | <1% | 4,689 | $26K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 634 | $25K |
| 81025 | <1% | 10,031 | $24K | |
| 0450 | Emergency room services | <1% | 449 | $24K |
| 10060 | <1% | 187 | $21K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,117 | $21K |
| 74018 | <1% | 1,780 | $21K | |
| 80047 | <1% | 4,105 | $20K | |
| 76801 | <1% | 649 | $20K | |
| 83605 | <1% | 3,299 | $19K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,634 | $18K |
| 73030 | <1% | 1,289 | $18K | |
| 12001 | <1% | 270 | $18K | |
| 73110 | <1% | 829 | $17K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 473 | $16K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,005 | $16K |
| 72100 | <1% | 1,204 | $16K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 87 | $16K |
| 82550 | <1% | 6,164 | $16K | |
| 59025 | Fetal non-stress test | <1% | 147 | $15K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,451 | $15K |
| 97163 | <1% | 818 | $15K | |
| 82077 | <1% | 3,512 | $14K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,167 | $14K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 429 | $13K |
| 85610 | <1% | 10,917 | $13K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,416 | $13K |
| 93970 | <1% | 247 | $13K | |
| 85730 | <1% | 8,057 | $13K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,812 | $13K |
| 93976 | <1% | 179 | $12K | |
| 83735 | <1% | 7,598 | $12K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 9,709 | $12K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,459 | $11K |
| 87088 | <1% | 3,701 | $11K | |
| 87420 | <1% | 1,104 | $11K | |
| 97161 | <1% | 332 | $10K | |
| J3490 | Unclassified drugs | <1% | 3,160 | $9K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,193 | $9K |
| 85379 | <1% | 2,359 | $9K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,076 | $8K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 446 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,440 | $7K |
| 70496 | <1% | 61 | $7K | |
| 87077 | <1% | 1,687 | $7K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,407 | $7K |
| 87210 | <1% | 1,679 | $7K | |
| 70486 | <1% | 90 | $6K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 87 | $6K |
| 12011 | <1% | 84 | $6K | |
| 81003 | <1% | 5,434 | $5K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 53 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,206 | $5K |
| 73502 | <1% | 285 | $5K | |
| 86901 | <1% | 5,226 | $4K | |
| 86900 | <1% | 5,227 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,149 | $4K |
| 97165 | <1% | 187 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,189 | $4K |
| C1776 | Joint device (implantable) | <1% | 53 | $4K |
| 84100 | <1% | 4,480 | $4K | |
| 86920 | <1% | 346 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,905 | $4K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,188 | $4K |
| 97162 | <1% | 219 | $3K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 165 | $3K |
| 73080 | <1% | 201 | $3K | |
| 86850 | <1% | 2,981 | $3K | |
| 87186 | <1% | 816 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,194 | $3K |
| 80061 | Lipid panel | <1% | 813 | $3K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,004 | $3K |
| 72050 | <1% | 128 | $3K | |
| 76857 | <1% | 107 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,857 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 651 | $2K |
| 72131 | <1% | 39 | $2K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 2,172 | $2K |
| 97166 | <1% | 89 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 728 | $2K |
| 85007 | <1% | 1,547 | $2K | |
| 70491 | <1% | 25 | $2K | |
| 95816 | <1% | 14 | $2K | |
| 97116 | <1% | 175 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,808 | $2K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,436 | $2K |
| 73590 | <1% | 120 | $2K | |
| 76770 | <1% | 26 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 212 | $1K |
| 76942 | <1% | 159 | $1K | |
| 84439 | <1% | 432 | $1K | |
| 93017 | <1% | 87 | $1K | |
| 73140 | <1% | 45 | $1K | |
| 93356 | <1% | 285 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,142 | $1K |
| 29125 | <1% | 13 | $899.30 | |
| 73090 | <1% | 41 | $804.50 | |
| 70498 | <1% | 16 | $714.45 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 86 | $706.17 |
| 86140 | <1% | 487 | $670.24 | |
| 86592 | <1% | 109 | $664.71 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,317 | $630.61 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,434 | $621.74 |
| 96368 | <1% | 92 | $536.94 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 484 | $532.70 |
| 71101 | <1% | 28 | $517.32 | |
| 99152 | <1% | 193 | $507.11 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 725 | $475.31 |
| 82553 | <1% | 176 | $448.64 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 174 | $421.73 |
| 82248 | <1% | 962 | $417.55 | |
| 80069 | <1% | 410 | $413.69 | |
| 84112 | <1% | 13 | $401.75 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,007 | $366.27 |
| 96367 | <1% | 27 | $355.77 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,297 | $353.90 |
| 73560 | <1% | 29 | $322.98 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 149 | $308.80 |
| 15853 | <1% | 14 | $275.00 | |
| 0250 | <1% | 45 | $230.51 | |
| 72072 | <1% | 12 | $229.92 | |
| 85651 | <1% | 268 | $221.16 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 139 | $170.51 |
| 36430 | <1% | 33 | $161.65 | |
| 82607 | <1% | 64 | $149.77 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,703 | $144.84 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 487 | $124.78 |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 16 | $116.10 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 139 | $115.49 |
| J7999 | Compounded drug, not otherwise classified | <1% | 62 | $96.92 |
| 76870 | <1% | 12 | $89.22 | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 39 | $81.60 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,740 | $80.74 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 179 | $78.77 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 63 | $64.24 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 16 | $59.04 |
| 82140 | <1% | 19 | $49.70 | |
| 88304 | <1% | 98 | $45.34 | |
| 82746 | <1% | 13 | $40.12 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 150 | $39.78 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 59 | $38.33 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $32.86 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 20 | $32.04 |
| 84132 | <1% | 259 | $25.12 | |
| 85018 | <1% | 39 | $22.68 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 16 | $21.22 |
| 83550 | <1% | 13 | $9.56 | |
| 85049 | <1% | 26 | $9.49 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 19 | $7.80 |
| 83540 | <1% | 13 | $7.78 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 14 | $2.38 |
| A9270 | Non-covered item or service | 0% | 15,300 | $0.00 |
| C1769 | Guide wire | 0% | 441 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 13 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 14 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 670 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 13 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 184 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHWAN, JASON (CFO)